--- title: "Zevra Therapeutics (ZVRA) Following EMA Setback Is The Sell Off A Valuation Gap" type: "News" locale: "en" url: "https://longbridge.com/en/news/293819040.md" description: "Zevra Therapeutics (ZVRA) shares dropped nearly 24% following a negative CHMP opinion on arimoclomol for Niemann Pick disease type C. Despite short-term volatility, analysis suggests the stock may be undervalued, with a fair value estimate of $15.40 compared to its recent trading price near $13. The sell-off is viewed by some as a valuation gap rather than a permanent reset, though risks remain regarding potential EMA rejection or disappointing Phase 3 data." datetime: "2026-07-25T09:24:05.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/293819040.md) - [en](https://longbridge.com/en/news/293819040.md) - [zh-HK](https://longbridge.com/zh-HK/news/293819040.md) generator: "portal-rs" --- # Zevra Therapeutics (ZVRA) Following EMA Setback Is The Sell Off A Valuation Gap Zevra Therapeutics (ZVRA) is back in focus after the European Medicines Agency’s CHMP issued a negative opinion on arimoclomol for Niemann Pick disease type C, prompting a planned re examination and a sharp share price reaction. See our latest analysis for Zevra Therapeutics. The CHMP setback has hit sentiment hard in the short term, with Zevra Therapeutics’ share price down 23.92% over one day and 27.18% over 30 days. However, its year to date share price return of 14.21% and three year total shareholder return of 97.20% show that longer term investors have still seen meaningful gains, despite a 15.18% decline in the one year total shareholder return. If this kind of volatility has you looking for other opportunities in healthcare, it could be a good moment to see what else is moving with our screener of 39 healthcare AI stocks. After a one day drop of nearly 24%, Zevra Therapeutics now trades at a steep discount to analyst price targets and an estimated intrinsic value. Is the market simply being cautious about regulatory risk, or overly pessimistic about what the pipeline is worth? ## Most Popular Narrative: 38.1% Undervalued Compared with the last close at $9.53, the most followed narrative on Zevra Therapeutics points to a fair value of $15.40. This frames the recent sell off as a potential valuation gap rather than a permanent reset. > *The calculated fair value range is approximately $14 to $18, with a midpoint of $15.50. At a current trading price near $13, the stock is fairly valued to slightly undervalued based on existing fundamentals, but it does not represent a deep value opportunity.* *Read the complete narrative.* Curious how this narrative gets to a fair value well above today’s $9.53 price? The core argument hinges on how MIPLYFFA cash flows, pipeline rNPV and sizeable cash balances are combined into a single sum of the parts story, with a few key assumptions doing most of the heavy lifting. **Result: Fair Value of $15.40 (UNDERVALUED)** Have a read of the narrative in full and understand what's behind the forecasts. However, this Zevra Therapeutics narrative could be challenged if EMA re examination still results in an arimoclomol rejection, or if Phase 3 data disappoints. Find out about the key risks to this Zevra Therapeutics narrative. ## Next Steps With sentiment clearly split on Zevra Therapeutics, do you want to rely on headlines or check the details for yourself and move quickly to form your own view by weighing both the upside potential and the areas of concern highlighted in the 5 key rewards and 2 important warning signs? ## Looking for more investment ideas beyond Zevra Therapeutics? If you are weighing what to do next after this Zevra Therapeutics update, it makes sense to line up a few fresh ideas before the market moves on. - Spot potential bargains early by scanning a focused list of screener containing 20 high quality undiscovered gems that combine strong fundamentals with less crowd attention. - Strengthen the core of your portfolio by zeroing in on companies from our solid balance sheet and fundamentals stocks screener (49 results) that prioritize financial resilience. - Dial back portfolio stress by filtering for 81 resilient stocks with low risk scores that may offer a smoother ride when volatility picks up. *This article by Simply Wall St is general in nature. **We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.** It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.* ### Valuation is complex, but we're here to simplify it. Discover if Zevra Therapeutics might be undervalued or overvalued with our detailed analysis, featuring **fair value estimates, potential risks, dividends, insider trades, and its financial condition.** Access Free Analysis ### Related Stocks - [ZVRA.US](https://longbridge.com/en/quote/ZVRA.US.md) ## Related News & Research - [Zevra Therapeutics presents long-term real-world MIPLYFFA data in Niemann-Pick type C at SSIEM 2026](https://longbridge.com/en/news/296905592.md) - [Zevra Therapeutics Chief Legal & Compliance Rahsaan Thompson sells 42,666 shares for $474,781.44](https://longbridge.com/en/news/296143510.md) - [INmune Bio submits EMA orphan drug application for Ebstrocel in RDEB](https://longbridge.com/en/news/297032741.md) - [Is Emera (TSX:EMA) Undervalued Following Mixed Q2 2026 Earnings?](https://longbridge.com/en/news/296279084.md) - [Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields](https://longbridge.com/en/news/296911087.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**